Actively Recruiting
FUSION - NCT05798520 A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis

Please note, some trial-specific information on this page is sourced from clinicaltrials.gov.

About

Trial summary
TYPE Interventional
PHASE
Alternative text for Phase image

Phase

Clinical trials are done in different phases (0-4). Each phase provides important information about the drug. If a drug does not pass a particular phase, it cannot progress to the next phase. Visit the About Clinical Trials page to learn more.

Phase 2
CONDITION
  • Relapsing Forms of Multiple Sclerosis
  • INTERVENTIONS
    Interventions tooltip icon

    Interventions

    The drug, device, or procedure being tested.

      Drug:BIIB091
      Administered as specified in the treatment arm.
      Drug:DRF
      Administered as specified in the treatment arm.
      Drug:Placebo
      Administered as specified in the treatment arm.
    ENROLLMENT
    Icon tooltip

    Enrollment

    The number of participants needed to take part in this trial.

    275 participants
    (Estimated)
    18 Years to 55 Years
    (Adult)
    LOCATIONS 74
    Key dates
    Alternative text for Keydates image

    Key dates

    When the trial is conducted - from the date the first participant is enrolled to the date of the last participants's final visit.

    July 25, 2023
    Trial start date
    November 9, 2026
    Trial end date (Estimated)
    More Information
    OTHER STUDY IDs
      257MS201

      2022-502552-31

    Clinical Trials Gov ID NCT05798520
    Last Updated

    We are currently unable to share site locations for this clinical trial. Please use the link to view (or find) site locations:

    CLINICALTRIALS.GOV

    Results

    The results of this clinical trial may not be available, especially if the clinical trial has not completed.

    We're committed to sharing information about our clinical research in alignment with global legal requirements, the industry trade association principles, and internal company policies. Generally, results summaries for clinical trials in approved products are available within one year of the trial completion. Please refer to Biogen's transparency & data sharing policy for more information.

    Clinical trial registers

    Clinical trial registers, like clinicaltrials.gov, provide information about registered clinical trials. 

     

    Publishing results for completed clinical trials on clinical trial registers help us share information about our clinical research. The results we publish here are written for healthcare professionals.

    CLINICALTRIALS.GOV
    Contact Us

    Please contact a clinical trial site directly to learn more about the trial. If no contact details are available, or for general inquiries, please contact the Biogen Clinical Trial Center.

    United States Biogen Clinical Trial Center

    866-633-4636

    clinicaltrials@biogen.com

    Find a trial location